FDA grants AP status for Quetiapine Fumarate ANDA206252 by Accord Healthcare
The FDA has granted approval status (AP) for the ANDA206252 application for Quetiapine Fumarate submitted by Accord Healthcare.
Asset
Quetiapine
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Accord Healthcare's ANDA for Quetiapine Fumarate signifies a potential shift in the competitive landscape for antipsychotic medications. This could lead to pricing pressures and market share erosion for existing branded products and other generics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for market launch and any subsequent competitive responses from other manufacturers.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.